%3Amax_bytes(150000)%3Astrip_icc()%2FTAL-woman-in-copenhagen-HAPPYCITY0525-eea7646175dc475c830554626bf8cfb2.jpg&w=3840&q=100)
This Is the Happiest City in the World Right Now—and No, It's Not in Finland
Copenhagen, Denmark, was named the happiest city in the world.
Zurich ranked second, while Singapore placed third; last year's winner, Aarhus, also in Denmark, is in fourth.
The highest-ranking U.S. cities on the list are New York, which came in 17th, and Minneapolis, which took the 30th spot.
If you're looking for a little more happiness in your life, consider moving to Denmark, home to the happiest city on the planet.
Each year, the Institute for Quality of Life releases its Happy City index, ranking cities "committed to cultivating and growing happiness" based on factors such as education, inclusive policies, the economy, environmental protection, and access to green areas. Overall, the organization looks at 82 different indicators of joy, including individual interviews with residents in cities across the globe.
And this year's list is topped by Copenhagen. According to the findings, the Danish capital ranks high thanks to its "commitment to education and innovation," as well as its transparency in governance, sustainability, and access to health care.
"Health and well-being are cornerstones of life in Copenhagen," the report noted. "The city boasts universal health care coverage, with every resident insured and access to 4.4 doctors per 1,000 inhabitants. Life expectancy stands at 79.9 years, supported by a well-balanced lifestyle that includes an average workweek of 37 hours."
Zurich, Switzerland, was second, followed by Singapore. Another Danish city, Aarhus, which topped the ranking in 2024, is fourth, and Antwerp, Belgium, is fifth. Denmark, which was named the second-happiest country in the world earlier this year after Finland, has seven cities in the top 50 alone.
The highest-ranking U.S. cities on this year's list are New York, which came in at No. 17, and Minneapolis, which is 30th.
However, the Institute for Quality of Life notes, "If there's one takeaway from our extensive research, it's this: no single city can be labelled as the absolute best at ensuring the happiness of its citizens over the long haul [...] At best, we might highlight cities for specific achievements or improvements in a given year. But that's not our main goal. We're all about uncovering and celebrating positive trends that boost happiness around the world."
See the full rankings and details of each city at happy-city-index.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
a day ago
- Miami Herald
Lilly's experimental obesity drug shows promise in early study
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market. The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Association conference in Chicago. The drug is moving to the next stage of development and researchers will present details on dosing and safety at the conference next week. "The data look particularly strong, and should push the program back into investor conversations," Cantor Fitzgerald analyst Prakhar Agrawal wrote in a note to investors. Lilly has shared few details about eloralintide before now, as it's still in the early stages of testing. It's part of a class of drugs that mimic the hormone amylin, which slows digestion and makes people feel full longer. They're thought to be a gentler option for losing weight than currently available injections like Zepbound and Wegovy, which often have side effects like nausea and vomiting. The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks. Weight loss ranged from 2.6% to 11.3%, according to the abstract. Gastrointestinal side effects were relatively minimal, with about 10% of patients experiencing diarrhea and 8% vomiting. Few details were provided, however, including information on risks and benefits based on dose. The promise of drugs that are easier to take than blockbusters like Lilly's Zepbound and its rival Wegovy, from Novo Nordisk A/S, has drawn increasing interest from companies hoping for a piece of pharma's hottest market. In March, Roche Holding AG entered into a $5.3 billion deal to co-develop and commercialize Zealand Pharma A/S' amylin drug, called petrelintide. It is seen as the one to beat in the amylin class, with early trials showing patients lost as much as 8.6% of their body weight in four months, with less nausea than Lilly and Novo's current therapies. AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market. New York-based startup Metsera Inc. is developing a related compound that may be taken less frequently than weekly shots like Zepbound and Wegovy. Lilly is already a leader in the obesity market, where Zepbound is capturing the majority of new prescriptions. The company has several promising next-generation products in the late stages of development, including a pill called orforglipron and an experimental shot that's thought to be even more effective for weight loss. The company is studying eloralintide alone and in combination with Zepbound - similar to the approach Novo is taking with its next-generation drug CagriSema, which combines an amylin component with semaglutide, the backbone of Wegovy and the diabetes drug Ozempic. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Yahoo
2 days ago
- Yahoo
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese. The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said. Amycretin, the Danish drugmaker's next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug Wegovy, amycretin not only mimics the gut hormone GLP-1, but also the effect of a hunger-suppressing pancreatic hormone called amylin. Weekly injections of the drug helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results published in January. Last year, the pill version helped patients lose up to 13.1% of their weight after 12 weeks in early-stage trial. Novo is also developing another two-drug combination, known as CagriSema, which, too, targets the amylin hormone. The company has launched a new late-stage trial for the drug, the U.S. government's trial database showed this week, as it tries to reassure the market of its potential after disappointing data from two previous studies. Novo had positioned CagriSema as a more potent successor to its blockbuster obesity treatment Wegovy, but lower-than-expected weight loss stoked worries that Eli Lilly may be gaining an edge over the company in the market for such drugs.
Medscape
3 days ago
- Medscape
A1c 6.7%-7.1% Tied to Improved Outcomes in Severe CKD
A Danish nationwide study of nearly 30,000 patients with diabetes and severe chronic kidney disease (CKD) showed that maintaining A1c levels between 6.7% and 7.1% minimised long-term complications, challenging current conservative glycaemic targets in this high-risk population. METHODOLOGY: Researchers conducted this nationwide registry-based cohort study to investigate the association between A1c levels and complications in 27,113 patients with diabetes and severe CKD (median age, 77.4 years; 53.6% men; type 1 diabetes, 30.5%). Severe CKD was defined by two registered estimated glomerular filtration rate (eGFR) measurements < 30 mL/min/1.73 m 2 at least 90 days apart. at least 90 days apart. Patients were matched to two reference groups: 80,131 individuals with diabetes and mild-to-moderate CKD (eGFR, 30-59 mL/min/1.73 m 2 ) and 80,797 individuals with diabetes and no-to-mild CKD (eGFR ≥ 60 mL/min/1.73 m 2 ). ) and 80,797 individuals with diabetes and no-to-mild CKD (eGFR ≥ 60 mL/min/1.73 m ). The 1-year risk for major adverse cardiovascular events, microvascular complications, and hospitalisations due to hypoglycaemia was estimated across A1c levels. The median follow-up duration was 5.4 years for patients with severe CKD. TAKEAWAY: The risk for major adverse cardiovascular events significantly increased at A1c levels ≥ 7.2% and < 5.8% compared with an A1c level of 6.3%-6.6% ( P < .01 and P < .001, respectively). < .01 and < .001, respectively). The risk for microvascular complications significantly increased at A1c levels ≥ 7.2% ( P < .001), and the risk for hospitalisation due to hypoglycaemia significantly increased at A1c levels ≥ 6.7% ( P < .001). < .001), and the risk for hospitalisation due to hypoglycaemia significantly increased at A1c levels ≥ 6.7% ( < .001). The relationship between A1c and outcomes remained consistent across sex, age, and diabetes type subgroups. Also, the relationship between A1c and long-term complications in patients with severe CKD mirrored that seen in those with no-to-mild or mild-to-moderate CKD. IN PRACTICE: "Overall, an HbA1c range of 6.7–7.1% (50–54 mmol/mol) seems to be the most favorable in regard to long-term complications and death in individuals with severe CKD. This is aligned with current guidelines, which recommend an HbA1c target of approximately 7% (53 mmol/mol) in individuals with diabetes and CKD. Our data do not support the current recommendations that propose conservative glycemic treatment of those with severe CKD," the authors wrote. SOURCE: This study was led by Dea H. Kofod, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. It was published online on June 07, 2025, in Diabetes Care . LIMITATIONS: Due to the observational nature of this study, researchers could not conclude whether high or low A1c levels caused poor outcomes in patients with severe CKD. The study lacked data on non-hospitalised hypoglycaemic events or dosages of insulin and other glucose-lowering medications. Additionally, the analyses were based on baseline A1c values as measurements beyond baseline were not collected systematically, and the study could not account for changes during follow-up. DISCLOSURES: This study was supported by grants from the Augustinus Foundation, the Danish Society of Nephrology's research foundation, Skibsreder Per Henriksen, R. og Hustru's Fond, Johnny Weileby's Fond, and Helen og Ejnar Bjørnow's Fond. Kofod reported receiving speaker honoraria from Bayer outside the submitted work. Some authors reported receiving speaker honoraria, research grants, and speaking fees; serving as advisors, speakers, and lecturers; and having other ties with various pharmaceutical companies.
